Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer

Judith Michels, Ilio Vitale, Laura Senovilla, David P. Enot, Pauline Garcia, Delphine Lissa, Ken A. Olaussen, Catherine Brenner, Jean Charles Soria, Maria Castedo, Guido Kroemer

Research output: Contribution to journalArticlepeer-review

Abstract

Abbreviations: CDDP, cisplatin; CEP, CEP 8983; DiOC6(3), 3′-dihexyloxacarbocyanine iodide; Δψm, mitochondrial transmembrane potential; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; NSCLC, non-small cell lung carcinoma; PARP, poly(ADP-ribose) polymerase; PI, propidium iodide; PJ, PJ34 hydrochloride hydrate; siRNA, small-interfering RNA.

Original languageEnglish
Pages (from-to)877-883
Number of pages7
JournalCell Cycle
Volume12
Issue number6
DOIs
Publication statusPublished - Mar 15 2013

Keywords

  • A549 cells
  • Apoptosis
  • CEP 8983
  • DNA damage response
  • PJ34 hydrochloride
  • Small-interfering RNAd

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Biology
  • Developmental Biology

Fingerprint Dive into the research topics of 'Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this